Top

Published in:

01-12-2019 | Small Bowel Resection | Original Article

Novel effect of glucagon-like peptide-2 for hepatocellular injury in a parenterally fed rat model of short bowel syndrome

Authors: Keisuke Yano, Tatsuru Kaji, Shun Onishi, Seiro Machigashira, Taichiro Nagai, Toshio Harumatsu, Koji Yamada, Waka Yamada, Mitsuru Muto, Kazuhiko Nakame, Motoi Mukai, Satoshi Ieiri

Published in: Pediatric Surgery International | Issue 12/2019

Abstract

Purpose

Short bowel syndrome (SBS) patients require long-term parenteral nutrition following massive bowel resection, which causes intestinal failure-associated liver disease (IFALD). Previous reports have shown that glucagon-like peptide-2 (GLP-2) resulted in the bowel adaptation for SBS. The aim of this study was to evaluate the effect of GLP-2 for IFALD in a parenterally fed rat model.

Methods

Using rat, a catheter was placed in the jugular vein, and 90% small bowel resection (SBR) was performed. Animals were divided into three groups: SBR and total parenteral nutrition (TPN) (SBS/TPN group), SBR and TPN plus GLP-2 at 1 µg/kg/h [SBS/TPN/GLP-2 (low) group], and SBR and TPN plus GLP-2 at 10 µg/kg/h [SBS/TPN/GLP-2 (high) group]. On day 13, the liver was harvested and analyzed by using nonalcoholic fatty liver disease (NAFLD) score.

Results

Histologically, hepatic steatosis in the SBS/TPN group and SBS/TPN/GLP-2 (high) group was observed. Both steatosis and lobular inflammation score in the SBS/TPN/GLP-2 (low) group were significantly lower compared with those in the other two groups (p < 0.05). Active NAFLD score in the SBS/TPN/GLP-2 (low) group was significantly lower compared with that in the SBS/TPN/GLP-2 (high) group (p < 0.01).

Conclusion

Low-dose GLP-2 intravenous administration improves hepatic steatosis of IFALD following in an SBS parenterally fed rat model.

Coletta R, Khalil BA, Morabito A (2014) Short bowel syndrome in children: surgical and medical perspectives. Semin Pediatr Surg 23:291–297. https://doi.org/10.1053/j.sempedsurg.2014.09.010 CrossRefPubMed

Kelly DA (2006) Intestinal failure-associated liver disease: what do we know today? Gastroenterology 130(2 Suppl 1):S70–S77. https://doi.org/10.1053/j.gastro.2005.10.066 CrossRefPubMed

Kakino S, Ohki T, Nakayama H, Yuan X, Otabe S, Hashinaga T, Wada N, Kurita Y, Tanaka K, Hara K, Soejima E, Tajiri Y, Yamada K (2018) Pivotal role of TNF-alpha in the development and progression of nonalcoholic fatty liver disease in a murine model. Horm Metab Res 50:80–87. https://doi.org/10.1055/s-0043-118666 CrossRefPubMed

Onishi S, Kaji T, Yamada W, Nakame K, Moriguchi T, Sugita K, Yamada K, Kawano T, Mukai M, Souda M, Yamada S, Yoshioka T, Tanimoto A, Ieiri S (2016) The administration of ghrelin improved hepatocellular injury following parenteral feeding in a rat model of short bowel syndrome. Pediatr Surg Int 32(12):1165–1171. https://doi.org/10.1007/s00383-016-3975-1 CrossRefPubMed

Machigashira S, Kaji T, Onishi S, Yamada W, Yano K, Yamada K, Masuya R, Kawano T, Nakame K, Mukai M, Ieiri S (2018) The protective effect of fish oil lipid emulsions on intestinal failure-associated liver disease in a rat model of short-bowel syndrome. Pediatr Surg Int 34(2):203–209. https://doi.org/10.1007/s00383-017-4190-4 CrossRefPubMed

Sigalet DL (2001) ALX-0600 (NPS Allelix Corp). Curr Opin Investig Drugs 2(4):505–509PubMed

Kaji T, Tanaka H, Holst J, Redstone H, Wallace L, de Heuval E, Sigalet DL (2008) The effects of variations in dose and method of administration on glucagon like peptide-2 activity in the rat. Eur J Pharmacol 596(1–3):138–145. https://doi.org/10.1016/j.ejphar.2008.07.070 CrossRefPubMed

Lim DW, Wales PW, Josephson JK, Nation PN, Wizzard PR, Sergi CM, Field CJ, Sigalet DL, Turner JM (2016) Glucagon-like peptide 2 improves cholestasis in parenteral nutrition-associated liver disease. J Parenter Enteral Nutr 40(1):14–21. https://doi.org/10.1177/0148607114551968 CrossRef

Nabeshima A, Yamada S, Guo X, Tanimoto A, Wang KY, Shimajiri S, Kimura S, Tasaki T, Noguchi H, Kitada S, Watanabe T, Fujii J, Kohno K, Sasaguri Y (2013) Peroxiredoxin 4 protects against nonalcoholic steatohepatitis and type 2 diabetes in a nongenetic mouse model. Antioxid Redox Signal 19(17):1983–1998. https://doi.org/10.1089/ars.2012.4946 CrossRefPubMedPubMedCentral

10.

Nakame K, Kaji T, Mukai M, Shinyama S, Matsufuji H (2016) The protective and anti-inflammatory effects of glucagon-like peptide-2 in an experimental rat model of necrotizing enterocolitis. Peptides 75:1–7. https://doi.org/10.1016/j.peptides.2015.07.025 CrossRefPubMed

11.

Sigalet DL, Wallace LE, Holst JJ, Martin GR, Kaji T, Tanaka H, Sharkey KA (2007) Enteric neural pathways mediate the anti-inflammatory actions of glucagon-like peptide 2. Am J Physiol Gastrointest Liver Physiol 293(1):G211–G221. https://doi.org/10.1152/ajpgi.00530.2006 CrossRefPubMed

12.

El-Jamal N, Erdual E, Neunlist M, Koriche D, Dubuquoy C, Maggiotto F, Chevalier J, Berrebi D, Dubuquoy L, Boulanger E, Cortot A, Desreumaux P (2014) Glugacon-like peptide-2: broad receptor expression, limited therapeutic effect on intestinal inflammation and novel role in liver regeneration. Am J Physiol Gastrointest Liver Physiol 307(3):G274–G285. https://doi.org/10.1152/ajpgi.00389.2012 CrossRefPubMed

13.

Shi X, Zhou F, Li X, Chang B, Li D, Wang Y, Tong Q, Xu Y, Fukuda M, Zhao JJ, Li D, Burrin DG, Chan L, Guan X (2013) Central GLP-2 enhances hepatic insulin sensitivity via activating PI3K signaling in POMC neurons. Cell Metab 18(1):86–98. https://doi.org/10.1016/j.cmet.2013.06.014 CrossRefPubMedPubMedCentral

14.

Taher J, Baker C, Alvares D, Ijaz L, Hussain M, Adeli K (2018) GLP-2 dysregulates hepatic lipoprotein metabolism, inducing fatty liver and VLDL overproduction in male hamsters and mice. Endocrinology 159(9):3340–3350. https://doi.org/10.1210/en.2018-00416 CrossRefPubMed

15.

Schoeler M, Klag T, Wendler J, Bernhard S, Adolph M, Kirschniak A, Goetz M, Malek N, Wehkamp J (2018) GLP-2 analog teduglutide significantly reduces need for parenteral nutrition and stool frequency in a real-life setting. Therap Adv Gastroenterol 11:1–11. https://doi.org/10.1177/1756284818793343 CrossRef

Title: Novel effect of glucagon-like peptide-2 for hepatocellular injury in a parenterally fed rat model of short bowel syndrome
Authors: Keisuke Yano
Tatsuru Kaji
Shun Onishi
Seiro Machigashira
Taichiro Nagai
Toshio Harumatsu
Koji Yamada
Waka Yamada
Mitsuru Muto
Kazuhiko Nakame
Motoi Mukai
Satoshi Ieiri
Publication date: 01-12-2019
Publisher: Springer Berlin Heidelberg
Keywords: Small Bowel Resection
Nutrition
Small Bowel Resection
Published in: Pediatric Surgery International / Issue 12/2019
Print ISSN: 0179-0358
Electronic ISSN: 1437-9813
DOI: https://doi.org/10.1007/s00383-019-04560-8

At a glance: The STEP trials

Springer Medicine

Novel effect of glucagon-like peptide-2 for hepatocellular injury in a parenterally fed rat model of short bowel syndrome

Abstract

Purpose

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 12/2019

Protective effects of vitamin D against injury in intestinal epithelium

An intra-amniotic injection of mesenchymal stem cells promotes lung maturity in a rat congenital diaphragmatic hernia model

First steps in the development of a liquid biopsy in situ hybridization protocol to determine circular RNA biomarkers in rat biofluids

The 32nd International Symposium on Paediatric Surgical Research

Accelerated cell turnover 48 h after intestinal ischemia is NOTCH independent

Management of pediatric appendiceal carcinoid: a single institution experience from 5000 appendectomies